Drug Information
| General Information | ||||||
|---|---|---|---|---|---|---|
| Drug ID |
DR00056
|
|||||
| Drug Name |
Lamotrigine
|
|||||
| Synonyms |
3,5-Diamino-6-(2,3-dichlorophenyl)-1,2,4-triazine; 3,5-Diamino-6-(2,3-dichlorophenyl)-as-triazine; 6-(2,3-Dichlorophenyl)-1,2,4-triazine-3,5-diamine; 6-(2,3-Dichlorophenyl)-1,2,4-triazine-3,5-diyldiamine; BW 430C; BW-430C; Crisomet; Desitin Brand of Lamotrigine; EUR-1048; Faes Brand of Lamotrigine; GI 267119X; GW 273293; Glaxo Wellcome Brand of Lamotrigine; GlaxoSmithKline Brand of Lamotrigine; Juste Brand of Lamotrigine; L 3791; Labileno; Lamictal; Lamictal (TN); Lamictal Cd; Lamictal ODT; Lamictal XR; Lamictin; Lamictin (TN); Lamiktal; Lamitor; Lamotrigina; Lamotrigina [Spanish]; Lamotrigine (JAN/USAN/INN); Lamotrigine [USAN:INN:BAN]; Lamotriginum; Lamotriginum [Latin]
|
|||||
| Drug Type |
Small molecular drug
|
|||||
| Indication | Bipolar disorder [ICD11:6A60-6A61] | Approved | [1] | |||
| Epilepsy [ICD11:8A6Z] | Approved | [1] | ||||
| Therapeutic Class |
Anticonvulsants
|
|||||
| Structure |
|
 |
||||
| 3D MOL | 2D MOL | |||||
| Formula |
C9H7Cl2N5
|
|||||
| Canonical SMILES |
C1=CC(=C(C(=C1)Cl)Cl)C2=C(N=C(N=N2)N)N
|
|||||
| InChI |
InChI=1S/C9H7Cl2N5/c10-5-3-1-2-4(6(5)11)7-8(12)14-9(13)16-15-7/h1-3H,(H4,12,13,14,16)
|
|||||
| InChIKey |
PYZRQGJRPPTADH-UHFFFAOYSA-N
|
|||||
| CAS Number |
CAS 84057-84-1
|
|||||
| Pharmaceutical Properties | Molecular Weight | 256.089 | Topological Polar Surface Area | 90.7 | ||
| Heavy Atom Count | 16 | Rotatable Bond Count | 1 | |||
| Hydrogen Bond Donor Count | 2 | Hydrogen Bond Acceptor Count | 5 | |||
| XLogP |
1.4
|
|||||
| PubChem CID | ||||||
| PubChem SID |
103199382
,103940000
,104179107
,104304778
,11111377
,11113342
,111978157
,11528749
,117872151
,12013463
,121361621
,124658861
,124799528
,124880544
,124880545
,124880546
,14823602
,17405249
,24278792
,26719658
,29222992
,46386680
,46505408
,47810853
,48259345
,48416154
,50100261
,50104089
,50104090
,53777794
,53787568
,56423136
,5669156
,57322032
,58107296
,76843584
,7847420
,7979720
,81092819
,8152444
,85231112
,855818
,90341162
,91148150
,92304062
,92308151
,92308280
,92308924
,92709766
,93166952
|
|||||
| ChEBI ID |
ChEBI:6367
|
|||||
| TTD Drug ID | ||||||
| DT(s) Transporting This Drug | 1-Oct | Transporter Info | Organic cation transporter 1 | Substrate | [2] | |
| P-GP | Transporter Info | P-glycoprotein 1 | Substrate | [3] | ||
| References | ||||||
| 1 | Lamotrigine was approved by FDA. The official website of the U.S. Food and Drug Administration. (2019) | |||||
| 2 | Lamotrigine is a substrate for OCT1 in brain endothelial cells. Biochem Pharmacol. 2012 Mar 15;83(6):805-14. | |||||
| 3 | Several major antiepileptic drugs are substrates for human P-glycoprotein. Neuropharmacology. 2008 Dec;55(8):1364-75. | |||||
If you find any error in data or bug in web service, please kindly report it to Dr. Li and Dr. Fu.